small molecule

CERDELGA

ELIGLUSTAT TARTRATE

Loss of exclusivityDecember 2038latest FDA-listed patent expiry
CompanyGenzymeSee this company's full patent-cliff portfolio

Drug detail

Brand nameCERDELGA
Active ingredientELIGLUSTAT TARTRATE
StrengthEQ 84MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2014
Marketing statusRX

Listed patents

PatentExpiresType
10888544December 2038use U-3040
12465586June 2032use U-3043
10888547January 2031use U-3043
11458119November 2030substance, product
7196205June 2026substance

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found